Clinical Trial of Topiramate for Cocaine Addiction

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

September 30, 2011

Conditions
Cocaine Dependence
Interventions
DRUG

topiramate

"topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial"

BEHAVIORAL

Contingency Reinforcement

monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results

DRUG

placebo + NonCR

participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence

Trial Locations (1)

21224

Behavioral Pharmacology Research Unit, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Johns Hopkins University

OTHER

NCT00685178 - Clinical Trial of Topiramate for Cocaine Addiction | Biotech Hunter | Biotech Hunter